Haemonetics Co. (NYSE:HAE - Free Report) - Investment analysts at Zacks Research cut their FY2025 earnings per share estimates for shares of Haemonetics in a report issued on Wednesday, January 29th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings of $4.58 per share for the year, down from their prior estimate of $4.59. The consensus estimate for Haemonetics' current full-year earnings is $4.59 per share. Zacks Research also issued estimates for Haemonetics' Q3 2026 earnings at $1.31 EPS, FY2026 earnings at $5.17 EPS and FY2027 earnings at $5.91 EPS.
Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 22.67% and a net margin of 9.10%.
Several other brokerages have also weighed in on HAE. Raymond James upgraded shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 target price on the stock in a research report on Friday, November 8th. Needham & Company LLC restated a "buy" rating and issued a $112.00 price target on shares of Haemonetics in a report on Tuesday, December 3rd. Barrington Research reaffirmed an "outperform" rating and set a $108.00 price objective on shares of Haemonetics in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. began coverage on Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 target price on the stock. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Haemonetics currently has an average rating of "Moderate Buy" and an average target price of $108.78.
Read Our Latest Research Report on Haemonetics
Haemonetics Price Performance
Shares of NYSE:HAE traded down $8.29 on Monday, reaching $62.95. 3,476,898 shares of the company were exchanged, compared to its average volume of 873,365. The company has a 50-day moving average of $77.44 and a 200-day moving average of $78.73. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of 26.12, a price-to-earnings-growth ratio of 1.07 and a beta of 0.39. Haemonetics has a 1-year low of $61.43 and a 1-year high of $97.97.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new position in shares of Haemonetics in the second quarter valued at approximately $39,000. Nisa Investment Advisors LLC grew its stake in Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after acquiring an additional 632 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock worth $92,000 after purchasing an additional 240 shares during the period. KBC Group NV boosted its holdings in shares of Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after purchasing an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Haemonetics in the third quarter valued at $204,000. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
